Carl Power

1.1k total citations
33 papers, 805 citations indexed

About

Carl Power is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Carl Power has authored 33 papers receiving a total of 805 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Carl Power's work include Prostate Cancer Treatment and Research (8 papers), Immunotherapy and Immune Responses (4 papers) and Biomedical Ethics and Regulation (4 papers). Carl Power is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Immunotherapy and Immune Responses (4 papers) and Biomedical Ethics and Regulation (4 papers). Carl Power collaborates with scholars based in Australia, Canada and China. Carl Power's co-authors include Pamela J. Russell, John E.J. Rasko, Paul Cozzi, Yong Li, Tzong‐Tyng Hung, Aparajita Khatri, Jingli Hao, Weiwei Xiao, Peter Graham and Peter A. Bretscher and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Internal Medicine and PLoS ONE.

In The Last Decade

Carl Power

33 papers receiving 791 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carl Power Australia 18 296 227 222 166 106 33 805
Marco Gerling Sweden 13 319 1.1× 262 1.2× 166 0.7× 78 0.5× 61 0.6× 23 778
Masakazu Shimizu Japan 14 327 1.1× 142 0.6× 373 1.7× 109 0.7× 67 0.6× 25 1.0k
Jianying Gu China 18 427 1.4× 246 1.1× 116 0.5× 90 0.5× 184 1.7× 47 923
Pamela M.J. McLaughlin Netherlands 14 456 1.5× 348 1.5× 212 1.0× 62 0.4× 97 0.9× 22 893
Sandra Chapman United States 4 393 1.3× 296 1.3× 75 0.3× 208 1.3× 50 0.5× 4 892
Carla Guenther Finland 9 312 1.1× 189 0.8× 292 1.3× 82 0.5× 37 0.3× 14 841
Zane Kalniņa Latvia 16 570 1.9× 151 0.7× 157 0.7× 89 0.5× 98 0.9× 26 829
Fenge Li China 14 329 1.1× 296 1.3× 507 2.3× 74 0.4× 47 0.4× 31 1.1k
David Y. Chin Australia 14 473 1.6× 250 1.1× 98 0.4× 82 0.5× 146 1.4× 26 866
Xiaoli Wei China 13 332 1.1× 202 0.9× 217 1.0× 100 0.6× 45 0.4× 30 776

Countries citing papers authored by Carl Power

Since Specialization
Citations

This map shows the geographic impact of Carl Power's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Power with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Power more than expected).

Fields of papers citing papers by Carl Power

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl Power. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Power. The network helps show where Carl Power may publish in the future.

Co-authorship network of co-authors of Carl Power

This figure shows the co-authorship network connecting the top 25 collaborators of Carl Power. A scholar is included among the top collaborators of Carl Power based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl Power. Carl Power is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sang, Rui, Sheri Nixdorf, Tzong‐Tyng Hung, et al.. (2025). Unlocking the in vivo therapeutic potential of radiation-activated photodynamic therapy for locally advanced rectal cancer with lymph node involvement. EBioMedicine. 116. 105724–105724. 1 indexed citations
2.
Ikonomou, Laertis, Megan Munsie, Carl Power, et al.. (2024). Effective regulatory responses to predatory stem cell markets in Australia and Canada. Cell stem cell. 31(10). 1393–1397. 2 indexed citations
3.
Rasko, John E.J. & Carl Power. (2023). The deadly legacy of a stem cell charlatan. BMJ. 381. p1367–p1367. 2 indexed citations
4.
Power, Carl. (2021). Alex Brown: fighting for the health of Indigenous Australians. The Lancet Diabetes & Endocrinology. 9(3). 142–142. 2 indexed citations
5.
Rashid, Imran, Ghassan J. Maghzal, Yung‐Chih Chen, et al.. (2018). Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque. European Heart Journal. 39(35). 3301–3310. 87 indexed citations
6.
Bourne, Roger, Carl Power, Aritrick Chatterjee, et al.. (2014). Distinctive Water Diffusion Properties of Epithelia May Be the Key to Better Cancer Imaging Techniques. Asia-Pacific Journal of Clinical Oncology. 10. 24–24. 1 indexed citations
7.
Power, Carl, Geoffrey Watson, Gary Cowin, et al.. (2014). Microscopic diffusion properties of fixed breast tissue: Preliminary findings. Magnetic Resonance in Medicine. 74(6). 1733–1739. 7 indexed citations
8.
Xiao, Weiwei, Peter Graham, Jingli Hao, et al.. (2013). Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells. PLoS ONE. 8(8). e74253–e74253. 29 indexed citations
9.
Funnell, Alister P. W., Laura J. Norton, Ka Sin Mak, et al.. (2012). The CACCC-Binding Protein KLF3/BKLF Represses a Subset of KLF1/EKLF Target Genes and Is Required for Proper Erythroid Maturation In Vivo. Molecular and Cellular Biology. 32(16). 3281–3292. 35 indexed citations
10.
Hao, Jingli, Michele C. Madigan, Aparajita Khatri, et al.. (2012). In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of either CD44 or CD147. PLoS ONE. 7(8). e40716–e40716. 70 indexed citations
11.
Power, Carl & John E.J. Rasko. (2011). Promises and Challenges of Stem Cell Research for Regenerative Medicine. Annals of Internal Medicine. 155(10). 706–713. 15 indexed citations
12.
Xiao, Weiwei, Peter Graham, Carl Power, et al.. (2011). CD44 is a biomarker associated with human prostate cancer radiation sensitivity. Clinical & Experimental Metastasis. 29(1). 1–9. 30 indexed citations
13.
Hung, Tzong‐Tyng, Jeffrey Chan, Pamela J. Russell, & Carl Power. (2011). Zoledronic Acid Preserves Bone Structure and Increases Survival but Does Not Limit Tumour Incidence in a Prostate Cancer Bone Metastasis Model. PLoS ONE. 6(5). e19389–e19389. 28 indexed citations
14.
Hao, Jinwei, et al.. (2010). CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer. Current Cancer Drug Targets. 10(3). 287–306. 52 indexed citations
15.
Wang, Li, Hongmin Chen, Fenghua Liu, et al.. (2010). Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Letters. 300(2). 122–133. 24 indexed citations
16.
Power, Carl, et al.. (2010). Development of Th1 Imprints to rBCG Expressing a Foreign Protein: Implications for Vaccination against HIV-1 and Diverse Influenza Strains. SHILAP Revista de lepidopterología. 2010. 1–8. 1 indexed citations
17.
Power, Carl, et al.. (2009). A novel model of bone‐metastatic prostate cancer in immunocompetent Mice. The Prostate. 69(15). 1613–1623. 40 indexed citations
18.
Wang, Jian, Syed Rizvi, Michele C. Madigan, et al.. (2006). Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted α radioimmunoconjugates. The Prostate. 66(16). 1753–1767. 17 indexed citations
19.
Groth, Barbara Fazekas de St, et al.. (2002). Experimental models linking dendritic cell lineage, phenotype and function. Immunology and Cell Biology. 80(5). 469–476. 6 indexed citations
20.
Power, Carl, et al.. (1999). A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNγ-producing T cells. Journal of Immunological Methods. 227(1-2). 99–107. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Gerling Breakdown of academic impact, for papers by Masakazu Shimizu Breakdown of academic impact, for papers by Jianying Gu Breakdown of academic impact, for papers by Pamela M.J. McLaughlin Breakdown of academic impact, for papers by Sandra Chapman Breakdown of academic impact, for papers by Carla Guenther Breakdown of academic impact, for papers by Zane Kalniņa Breakdown of academic impact, for papers by Fenge Li Breakdown of academic impact, for papers by David Y. Chin Breakdown of academic impact, for papers by Xiaoli Wei
Rankless by CCL
2026